Tetrofosmin

382.45500

382.46

3J0KPB596Q

DTXSID70155591

64.10000

4.09620

447.1ºC

278.9ºC

Soluble

9.09E-08mmHg at 25°C

The toxicity of tetrofosmin as an individual agent has not been studied.

Refer to [DB09160]

Tetrofosmin is indicated to be used as a complex with technetium Tc-99m for scintigraphic imaging of the myocardium following separate administrations under exercise and/or resting conditions. It helps in the delineation of regions of reversible myocardial ischemia in absence of infarcted myocardium. This complex is also used for scintigraphic imaging of the myocardium to identify changes in perfusion induced by pharmacologic stress in patients with known or suspected coronary artery disease. This complex is indicated for the assessment of left ventricular function in patients evaluated for heart disease.|FDA Label

Refer to [DB09160]

After intravenous administration, tetrofosmin is rapidly cleared from the blood and taken up by the heart, skeletal muscle, liver, spleen and kidneys.|Refer to [DB09160]|This pharmacokinetic property has not been fully studied.

This pharmacokinetic property has not been fully studied.

Refer to [DB09160]

Tetrofosmin normal biodistribution makes it suitable to be used as a myocardial agent as it is uptaken by the myocardial tissue and it presents a very low redistribution after 3-4 hours of administration. After distribution, tetrofosmin is a lipophilic cationic agent which is passively diffused and accumulated in viable myocardial tissue.

Human drugs -> Rare disease (orphan)